Verndari Reports: Publication in the Journal Vaccine of Early Data Using VaxiPatch™ Vaccine System to Administer Flu Vaccine Reports

mJOULE Launches in the United Kingdom Reports Sciton

"Sciton is dedicated to worldwide support and growth. We continue to demonstrate our commitment to developing high quality devices and marketing efforts for our physician and medspa partners worldwide." says Lacee J. Naik, Vice President of Marketing and Public Relations.

FDA Issues Draft Guidance on Remanufacturing and Discussion Paper Seeking Feedback on Cybersecurity Servicing of Medical Devices

With this in mind, the FDA is issuing today's draft guidance to help clarify whether activities performed on medical devices are likely remanufacturing as well as a discussion paper on cybersecurity servicing of devices.

Irrimax Receives FDA Clearance for Irrisept

"This new clearance from the FDA further solidifies Irrisept as the market leader in wound irrigation," said Mark Alvarez, CEO of Irrimax.

Publication of preclinical data in the Journal Vaccine on Verndari novel vaccination system using a microneedle dermal patch was announced today.

The early study examined Verndari’s proprietary influenza vaccine administered with its patented VaxiPatch™ technology. Results showed a significantly increased immune response compared with an existing influenza vaccine.

“The Verndari VaxiPatch™ system holds the promise of enabling faster development of vaccines for new threats such as COVID-19 as well as more effective vaccines for existing viruses, such as influenza,” said Dr. Daniel R. Henderson, CEO of Verndari. “VaxiPatch™ eliminates the need for refrigeration, a major cost factor, and barrier to access throughout developing countries. By using microarray technologies that carry a temperature-stable vaccine, we can enable mass manufacturing, which is both cost-effective and increases global access to these life-saving treatments.”

For the preclinical study, Verndari used novel formulations of genetically engineered, single, purified protein antigens or “subunits,” along with novel formulations of adjuvants and its patented VaxiPatch microneedle array dermal patch. Verndari has created a single monovalent component of a quadrivalent seasonal flu vaccine that uses recombinant influenza hemagglutinin (rHA) as an antigen active ingredient for influenza virus B/Colorado/06/2017. The rHA functions in the FDA-approved single radial immunodiffusion (SRID) potency test. Verndari’s influenza vaccine configuration also allows the use of FDA-approved surrogate marker of influenza vaccine efficacy, the testing of the patient vaccine response by the hemagglutination inhibition test (HAI). This shortens clinical trial times to six weeks. Results showed that when compared with an existing influenza vaccine, Verndari obtained as much as a 15-fold higher immune response with 1/15 of the dose for the B/Colorado/06/2017 influenza strain.

spot_img

DON'T MISS

Hyperfine Adds Medtech Leader and Visionary Scott Huennekens as Executive Chairman

Mr. Huennekens’ public boards include Chairman of Acutus Medical (IPO August 2020); Chairman of Envista (IPO September 2019); and board member of Nuvasive. He also serves as a board member and past Chairman of the Medical Device Manufacturer’s Association (MDMA).

One Drop Reports Carrie Siragusa, CPA Appointed VP of Commercial Strategy, Biosensor

Formerly Head of Innovation and Diabetes Portfolio at Sanofi, Siragusa will be part of a team bringing a multi-analyte dermal sensor (biosensor) with continuous health sensing capabilities to market with a mission to provide broader access to continuous glucose monitoring.

Barbara Moorhouse Appointed as Medica Non-Executive Director

Barbara has extensive business and management experience in the private, public, and regulated sectors.

Subscribe to Medical Device News Magazine here.

Related Articles